|
ZNF84 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.90119994694749E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22399999971756E-07 |
| Normal-vs-Stage2 |
1.789580E-04 |
| Normal-vs-Stage3 |
2.92040003291305E-09 |
| Normal-vs-Stage4 |
1.0896000000038E-06 |
| Stage1-vs-Stage2 |
9.839000E-01 |
| Stage1-vs-Stage3 |
9.532100E-02 |
| Stage1-vs-Stage4 |
1.615360E-01 |
| Stage2-vs-Stage3 |
2.468200E-01 |
| Stage2-vs-Stage4 |
2.872000E-01 |
| Stage3-vs-Stage4 |
8.632200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.90729999466544E-08 |
| Normal-vs-AfricanAmerican |
1.743130E-03 |
| Normal-vs-Asian |
3.97770000000186E-05 |
| Caucasian-vs-AfricanAmerican |
8.766600E-01 |
| Caucasian-vs-Asian |
6.203000E-01 |
| AfricanAmerican-vs-Asian |
8.898400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.14020000000037E-06 |
| Normal-vs-Female |
2.56739995929678E-09 |
| Male-vs-Female |
3.356800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.39459999898884E-08 |
| Normal-vs-Age(41-60Yrs) |
4.61579999999628E-07 |
| Normal-vs-Age(61-80Yrs) |
2.29740000023959E-07 |
| Normal-vs-Age(81-100Yrs) |
7.980000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.327000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.967800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.253400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.199600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.653200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.865800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.220680E-04 |
| Classical-VS-Follicular |
3.725000E-01 |
| Classical-VS-Other |
9.758800E-01 |
| Classical-VS-Normal |
1.59589999992882E-07 |
| Tall-VS-Follicular |
1.916070E-02 |
| Tall-VS-Other |
2.740000E-01 |
| Tall-VS-Normal |
1.11569997685024E-09 |
| Follicular-VS-Other |
7.652400E-01 |
| Follicular-VS-Normal |
2.27669999999236E-05 |
| Other-VS-Normal |
9.023900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.20689999608226E-08 |
| Normal-vs-N1 |
2.43369999999299E-05 |
| N0-vs-N1 |
9.347200E-01 |
|
|
